vVARDIS

vVARDIS (Ticker: VVVV US) develops peptide-based dental products for early-stage tooth decay. Its peptide-containing formulations are intended to help stop early cavity progression, preserve natural tooth structure and repair damaged enamel. Its flagship products are Curodont Repair Fluoride Plus, sold in the United States, and Curodont Repair, sold in other markets. Founded in Switzerland by dentists Dr. Haley Abivardi and Dr. Goly Abivardi, the company estimated that its products had treated more than 3.5 million teeth as of June 30, 2026. They had been sold to more than 20,000 of approximately 110,000 U.S. general dental practices.

For 2025, vVARDIS reported net revenue of $30.20 million and gross profit of $22.40 million. For the six months ended June 30, 2026, it reported net revenue of $28.60 million and gross profit of $24.70 million. Net losses were $56.45 million in 2025 and $27.81 million in the first half of 2026.

vVARDIS expects to begin trading on NYSE on November 13, 2026. Pricing is scheduled for November 12, 2026 after market close. The base offering comprises 9,523,810 newly issued shares at an indicative price range of $21.00–$24.00 per share. At the $22.50 midpoint, the offering represents approximately $214.29 million in gross proceeds. The company estimated net proceeds of approximately $191.10 million at the midpoint, after underwriting discounts, commissions and estimated offering expenses. Proceeds are intended for working capital, operating expenses and capital expenditures.

Underwriters include Goldman Sachs, J.P. Morgan and UBS Investment Bank.